ResMed Inc.
ResMed Inc. (RMD) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
rmd · pe ratio · data through Jun 30, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for ResMed Inc. (RMD) measures how much investors pay for each dollar of the company's trailing earnings. RMD's current PE ratio of 18.73x is calculated by dividing its stock price of $193.39 by its TTM earnings per share of $10.37. −54.2% discount vs 5Y avg 40.9x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-06-30
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 20 fiscal years · Front-end computedMinQ1 · 25%27.0x
MedianQ3 · 75%75.5x
Max
At 18.73x, RMD's current P/E is lower than in 5% of its annual fiscal year readings over the past 20 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Devices · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
ResMed Inc.You RMD | $28.1B | 18.73x | -30.3% | $10.37 |
 Agilent Technologies, Inc. A | $37.5B | 31.79x | +18.3% | $4.60 |
 Alcon Inc. ALC | $32.3B | 39.80x | +48.1% | $1.98 |
 Becton, Dickinson and Company BDX | $54.3B | 25.13x | -6.5% | $5.85 |
 Cardinal Health, Inc. CAH | $47.9B | 25.94x | -3.5% | $6.48 |
 GE HealthCare Technologies Inc. GEHC | $29.5B | 17.97x | -33.1% | $4.56 |
 Haleon plc HLN | $39.5B | 20.62x | -23.3% | $0.36 |
Industry Average 6 peers with valid PE | — | 26.87x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-06-30Latest FY2025 | 27.02x | $9.55 | +0.4% | |
2024-06-30 FY2024 | 26.92x | $6.94 | -24.7% | |
2023-06-30 FY2023 | 35.73x | $6.12 | -9.1% | |
2022-06-30 FY2022 | 39.28x | $5.34 | -48.0% | |
2021-06-30 FY2021 | 75.49x | $3.27 | +69.4% | |
2020-06-30 FY2020 | 44.58x | $4.31 | +1.8% | |
2019-06-30 FY2019 | 43.78x | $2.83 | -6.6% | |
2018-06-30 FY2018 | 46.86x | $2.21 | +45.7% | |
2017-06-30 FY2017 | 32.16x | $2.42 | +27.8% | |
2016-06-30 FY2016 | 25.16x | $2.51 | +12.1% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for ResMed Inc. (RMD) measures how much investors pay for each dollar of the company's trailing earnings. RMD's current PE ratio of 18.73x is calculated by dividing its stock price of $193.39 by its TTM earnings per share of $10.37.
Frequently asked questions
RMD pe ratio · 6 questionsRMD's current PE ratio is 18.73x as of 2026-06-08, based on a stock price of $193.39 and TTM EPS of $10.37. Data sourced from Financial Modeling Prep via RMD's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · ResMed Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08